Findings published in the latest issue of Cancer Prevention Research suggest that antiestrogen supplements help decrease the risk of subsequent melanoma in patients with breast cancer.
Since the debate about the safety of hormone replacement therapy began, researchers, patients, and clinicians have searched for a safe alternative to help alleviate the symptoms associated with menopause. Now, a small study in Italy suggests that dehydroepiandrosterone (DHEA) may be a solution.
Lymphedema, swelling caused by a blockage in the lymphatic system, can occur as a result of surgical or radiation therapy associated with breast cancer treatment. Since some research has shown that exercise after breast cancer treatment has been associated with developing lymphedema, clinicians often advise patients to avoid exercising. But is this truly necessary?
This KIDS COUNT Special Report contains some hopeful news for the future of America's families. Since 1991, the percentages of American teenagers getting pregnant, giving birth, or having abortions have all fallen.
Vulvodynia is a medical term that means "painful vulva". The term can cover a wide variety of vulvar pain syndromes, including various infections and skin disorders.
Painful sexual intercourse, called dyspareunia in medical terminology (pronounced "dis-pair-une-ee-ah"), is a common complaint among women seeking gynecologic care.
As we move along through this series of articles, try not be intimidated by "clinical" terms, such as 'personality disorder,' 'borderline,' 'sociopath,' etc. They are just words professionals have come to use in describing different technical aspects of mind and personality.
Good afternoon, everyone. Thank you, Ron. These are truly exciting times for us in providing contraception and healthcare to women, but with that excitement comes some responsibility.
“We just heard a presentation about one of the several new devices for contraception and you took part in a lot of research about this Transdermal Patches for contraception.
And my task for this afternoon is to review for you a new contraceptive option and what I’d like to do first is show you my disclosure statement and then I will go into the first part of discussion, talk about why I think there’s a need for this new contraception option and then go in much greater depth in discussing it.